Moleculin Biotech shares are trading higher after the company highlighted progress in its Phase 2/3 MIRACLE trial of Annamycin, including completed Part A enrollment and encouraging interim efficacy results.

8-K filing — Moleculin Biotech, Inc. (MBRX)

Filed: 2026-10-20 AccNo: 0001437749-26-032969 Size: 313 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Moleculin Biotech shares are trading lower after the company announced a 1-for-20 reverse stock split, effective October 20.

Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20